IPO Advisory
In-depth, experienced and seamless execution throughout the IPO Process.
IPO Detail
IPO Information
Financial
Financial Report
Peer Comparison
Peer Comparison
Performance
Performance Report
Gland Pharma IPO is a Book Building listing on BSE,NSE exchange, with an ipo size of ₹ 6479.55 Cr. The company is based in Hyderabad and caters to Pharmaceutical sector. Citigroup Global Markets India , Haitong Securities India , Kotak Mahindra Capital Company , Nomura Financial Advisory And Securities (India) are the merchant bankers of Gland Pharma IPO. It is a MainBoard IPO which filed its Draft Red Herring Prospectus (DRHP) on 10th July 2020.
Gland Pharma IPO posted revenues of ₹ 3,536.80 Cr. and PAT of ₹ 1,254.00 Cr. in FY21 on annualised basis.
Revenue:
₹ 3,536.80 Cr.
EBITDA Margin:
50.28
% 
Net Worth: ₹ 3963.40 Cr.
Market Capitalisation:
[●]
P/E:
19.50 times
P/BV: [●]
EV/EBITDA: -0.21 times
Financial results of Gland Pharma IPO based on restated financials as per prospectus and IPO review parameters can be referred to below.
| Financials | Jun-20 | FY 20 | FY 19 | FY 18 | |
|---|---|---|---|---|---|
|
Balance Sheet
|
|||||
| Assets | 4691.20 | 3688.50 | 4086.03 | 3523.50 | |
| Net Worth | 3963.40 | 3043.80 | 3646.20 | 2861.90 | |
| Total Debt | 4.00 | 4.90 | 4.00 | 4.96 | |
|
Profit & Loss
|
|||||
Revenue
Revenue on annualised basis |
884.20
3,536.80 |
674.40 | 263.32 | 20.44 | |
EBITDA
EBITDA on annualised basis |
444.60
1,778.40 |
296.90 | 1094.40 | 791.90 | |
PAT
PAT on annualised basis |
313.50
1,254.00 |
183.70 | 772.80 | 451.80 | |
Gland Pharma IPO PAT Margin is 35.46 % , ROCE (Return on Capital Employed) is [●] % as per latest financial. The below table shows Gland Pharma IPO Key Performance Indicators (KPI) as mentioned in company’s prospectus.
| Particulars | Jun-20 | FY 20 | FY 19 | FY 18 |
|---|---|---|---|---|
| EBITDA Margin (%) | 50.28 | 44.02 | 415.62 | 3,874.27 |
| PAT Margin (%) | 35.46 | 27.24 | 293.48 | 2,210.37 |
| EPS (₹) | 20.24 | 49.88 | 29.16 | 20.72 |
| ROE (%) | 7.91 | 6.04 | 21.19 | 15.79 |
| ROCE (%) | [●] | [●] | [●] | [●] |
| ROA (%) | 6.68 | 4.98 | 18.91 | 12.82 |
| Debt to Equity | 0.00 | 0.00 | 0.00 | 0.00 |
The market Capitalisation of Gland Pharma IPO is ₹ 0.00 crores at the time of IPO and other IPO valuation metrics of this IPO is mentioned below.
The Gland Pharma IPO prospectus highlights an Return on Equity (ROE) of 7.91 % , Return on Assets (ROA) of 6.68 %, and an EBITDA Margin of 50.28 %, showcasing financial performance.
Profitability ratios like Return on Equity (ROE), Return on Assets (ROA), and Net Profit Margin shows Gland Pharma IPO financial report. Analysing these metrics can provide insights into the company’s efficiency, profitability, and long-term growth potential.
The post-IPO market capitalisation of Gland Pharma IPO is ₹ 0.00 Cr., based on the issue price and share structure. It helps investors gauge the company’s valuation and compare it with industry peers before investing.
The Gland Pharma IPO has a Price-to-Earnings (PE) ratio of 19.50 X, indicating valuation compared to industry peers. It helps investors determine if the stock is overvalued or undervalued compared to its earnings and industry peers.
Gland Pharma IPO reported revenue of ₹ 3665.16 Cr. in the latest fiscal year, showing business performance, on annualised basis. Revenue figures from Gland Pharma IPO provide insights into sales growth, market demand, and business scalability.
Gland Pharma recorded an EBITDA of ₹ 1,778.40 Cr., reflecting operational efficiency. EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortisation) measures operational profitability.
Gland Pharma Profit After Tax (PAT) is ₹ 1,254.00 Cr., reflecting earnings growth. Profit After Tax (PAT) reflects the company’s actual earnings after all expenses, taxes, and deductions
Revenue:
₹ 3,536.80 Cr.
EBITDA Margin:
50.28
%
Net Worth: ₹ 3,963.40 Cr.
Market Capitalisation:
[●]
P/E:
19.50 times
P/BV: [●]
EV/EBITDA:
[●]
Gland Pharma operates in Pharmaceutical and Manufactures Inject Tables. The Issue is listed on BSE,NSE in Nov, 2020. Gland Pharma IPO size was 6479.55 with Issue price of 1500.00 .
Merchant Banker(s) of Gland Pharma IPO: Citigroup Global Markets India Private Limited , Haitong Securities India Private Limited , Kotak Mahindra Capital Company Limited , Nomura Financial Advisory And Securities (India) Private Limited
Gland Pharma IPO subscription was 2.06 X. IPO subscription refers to applications received in an IPO by each quota, i.e., QIB, Retail, and NII. In some IPOs, Eligible employee quota and shareholder’s quota are also present. Learn more about IPO subscriptions here.
Gland Pharma IPO listed at a listing price of 1820.45 against the offer price of 1500.00.
The current market price of Gland Pharma is 2000.30.
Why Us?
